XOMA Royalty Corporation (XOMA)
NASDAQ:XOMA
Top Page
XOMA Royalty Corporation
(NASDAQ:XOMA)
Select Model
Select Model
Rating:62Neutral
Price Target:
$29.00
▼(-0.75% Downside)
Action:ReiteratedDate:03/18/26
The score is driven primarily by improving fundamentals (profitability rebound) but constrained by weak cash-flow quality and elevated leverage. Valuation is supportive with a low P/E, while technicals are mixed (short-term strength vs longer-term trend). Corporate events are a net positive due to receipts growth and buybacks, tempered by legal risk.
Positive Factors
Portfolio expansion / aggregation
XOMA's addition of 22 assets and two platform technologies materially expands its royalty aggregation platform. A larger, early- and mid-stage focused portfolio increases diversification across programs and timelines, lowering single-asset concentration and creating a structural, multi-year pipeline of potential royalties and milestones as programs advance.
Negative Factors
Elevated leverage and balance-sheet sensitivity
XOMA's debt-to-equity of ~1.22 means material leverage for a royalty aggregator. Significant debt relative to equity reduces financial flexibility, increases refinancing and interest-rate exposure, and heightens the need for steady cash receipts; a drop in royalties or missed milestones could strain liquidity or limit opportunistic portfolio investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Portfolio expansion / aggregation
XOMA's addition of 22 assets and two platform technologies materially expands its royalty aggregation platform. A larger, early- and mid-stage focused portfolio increases diversification across programs and timelines, lowering single-asset concentration and creating a structural, multi-year pipeline of potential royalties and milestones as programs advance.
Read all positive factors
XOMA Royalty Corporation (XOMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$347.88M
Dividend YieldN/A
Average Volume (3M)53.64K
Price to Earnings (P/E)15.1
Beta (1Y)1.28
Revenue Growth118.02%
EPS GrowthN/A
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.26
Shares Outstanding11,905,652
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.60
Price to Sales (P/S)9.17
P/FCF Ratio166.54
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue7.83
Enterprise Value/Gross Profit8.30
Enterprise Value/Ebitda28.43
Forecast
1Y Price Target
$73.50Price Target Upside151.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.81
Revenue Forecast (FY)$63.71M
XOMA Royalty Corporation Business Overview & Revenue Model
Company Description
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associate...
How the Company Makes Money
XOMA makes money primarily by owning contractual economic interests in biopharmaceutical products and IP that are commercialized or developed by other companies. Its key revenue streams include: (1) Royalty income: XOMA receives a percentage of ne...
XOMA Royalty Corporation Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
56
Neutral
Cash Flow
45
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.15M | 28.49M | 4.76M | 6.03M | 38.16M |
| Gross Profit | 49.19M | 28.28M | 4.62M | 5.75M | 37.99M |
| EBITDA | 14.36M | -5.42M | -22.56M | -16.84M | 16.52M |
| Net Income | 31.71M | -13.82M | -40.83M | -17.10M | 15.80M |
Balance Sheet | |||||
| Total Assets | 272.70M | 221.28M | 234.30M | 140.38M | 166.56M |
| Cash, Cash Equivalents and Short-Term Investments | 82.91M | 105.18M | 153.45M | 58.16M | 94.10M |
| Total Debt | 131.56M | 119.20M | 124.45M | 34.00K | 229.00K |
| Total Liabilities | 168.74M | 139.36M | 145.58M | 16.37M | 24.69M |
| Stockholders Equity | 103.96M | 81.92M | 88.72M | 124.01M | 141.88M |
Cash Flow | |||||
| Free Cash Flow | 2.87M | -13.77M | -18.18M | -28.13M | -3.82M |
| Operating Cash Flow | 2.87M | -13.75M | -18.16M | -12.88M | 22.68M |
| Investing Cash Flow | 50.89M | -28.26M | -711.00K | -20.22M | -26.50M |
| Financing Cash Flow | -26.46M | -11.13M | 120.59M | -4.45M | 12.84M |
XOMA Royalty Corporation Technical Analysis
Positive
29.22
Price Trends
26.26
Positive
28.12
Positive
29.68
Negative
Market Momentum
0.81
Negative
63.91
Neutral
75.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XOMA, the sentiment is Positive. The current price of 29.22 is above the 20-day moving average (MA) of 27.09, above the 50-day MA of 26.26, and below the 200-day MA of 29.68, indicating a neutral trend. The MACD of 0.81 indicates Negative momentum. The RSI at 63.91 is Neutral, neither overbought nor oversold. The STOCH value of 75.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XOMA.
XOMA Royalty Corporation Risk Analysis
XOMA Royalty Corporation disclosed 3 risk factors in its most recent earnings report. XOMA Royalty Corporation reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XOMA Royalty Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $347.88M | 15.08 | 16.22% | ― | 118.02% | ― | |
55 Neutral | $1.15B | -39.78 | -23.29% | ― | ― | 79.27% | |
54 Neutral | $1.20B | -33.72 | -15.12% | ― | 1112.27% | ― | |
52 Neutral | $688.58M | ― | -2626.38% | ― | 14.26% | -23.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $922.00M | ― | -269.56% | ― | ― | ― |
* Healthcare Sector Average
XOMA
XOMA Royalty Corporation
30.20
9.07
42.92%
OCGN
Ocugen
1.95
1.21
163.87%
CRVS
Corvus Pharmaceuticals
14.22
10.87
324.48%
GLUE
Monte Rosa Therapeutics
15.71
10.22
186.16%
INBX
Inhibrx Biosciences Inc
66.46
52.22
366.71%
XOMA Royalty Corporation Corporate Events
Business Operations and StrategyStock BuybackFinancial Disclosures
XOMA Royalty Reports Strong 2025 Results and Growth
Positive
Mar 18, 2026
On March 18, 2026, XOMA Royalty reported its fourth-quarter and full-year 2025 results, posting $50.5 million in cash receipts, including $33.6 million in royalties and $16.9 million in milestones, a 9% increase in total receipts and a 68% jump in...
Business Operations and StrategyStock BuybackFinancial DisclosuresLegal Proceedings
XOMA Highlights Royalty Aggregation Strategy in Updated Presentation
Positive
Mar 2, 2026
On March 2, 2026, XOMA Royalty Corporation released an updated corporate presentation that highlights its differentiated position as a biotech royalty aggregator focused on smaller, early- to mid-stage clinical assets. The presentation underscores...
Business Operations and StrategyM&A Transactions
XOMA Royalty Completes Generation Bio Acquisition and Merger
Positive
Feb 9, 2026
On February 6, 2026, XOMA Royalty completed a tender offer to acquire approximately 70% of Generation Bio’s outstanding common shares at $4.2913 per share in cash plus one non‑tradeable contingent value right per share. The offer expir...
Business Operations and StrategyExecutive/Board Changes
XOMA Royalty Appoints New Chief Financial Officer
Positive
Jan 15, 2026
XOMA Royalty Corporation announced a leadership transition in its finance organization, effective January 12, 2026, with the appointment of 41-year-old industry veteran Jeffrey Trigilio as Chief Financial Officer, succeeding long-serving finance c...
Business Operations and StrategyFinancial Disclosures
XOMA Highlights Royalty Growth Strategy in Updated Presentation
Positive
Jan 12, 2026
On January 12, 2026, XOMA Royalty Corporation released an updated corporate presentation outlining its differentiated royalty-aggregation business model, current capitalization and growing portfolio of biotechnology-related royalty and milestone a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.